Patient‐reported outcomes of a phase II neoadjuvant apalutamide ( ARN ‐509) and radical prostatectomy in treatment of intermediate‐ to high‐risk prostate cancer ( NEAR ) trial
International Journal of Urology（2022）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要